Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade Gliomas

Status Active, not recruiting

Clinical Trial Summary

The purpose of this access protocol is to allow patients with brain tumors who had previously received 125I-MAB 425 to receive additional course(s) of 125I-MAB 425 until their brain tumor begins to grow, they develop side effects to the treatment, or their medical condition changes (e.g., you become pregnant, become infected with human immunodeficiency virus (HIV) or develop another cancer).

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01317888
Study type	Interventional
Source	Drexel University
Contact
Status	Active, not recruiting
Phase	N/A
Start date	January 2010

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05023551` - Study of DSP-0390 in Patients With Recurrent High-Grade Glioma	Early Phase 1
Recruiting	`NCT06059690` - Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells	Phase 1/Phase 2
Recruiting	`NCT04116411` - A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients	Phase 2
Terminated	`NCT01902771` - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors	Phase 1
Recruiting	`NCT03175224` - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Phase 2
Completed	`NCT02386826` - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme	Phase 1
Completed	`NCT00038493` - Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme	Phase 2
Withdrawn	`NCT03980249` - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells	Early Phase 1
Recruiting	`NCT01923922` - CT Perfusion in the Prognostication of Cerebral High Grade Glioma	N/A
Completed	`NCT01956734` - Virus DNX2401 and Temozolomide in Recurrent Glioblastoma	Phase 1
Completed	`NCT01402063` - PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation	Phase 2
Completed	`NCT01301430` - Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.	Phase 1/Phase 2
Suspended	`NCT01386710` - Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma	Phase 1/Phase 2
Active, not recruiting	`NCT00995007` - A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas	Phase 2
Terminated	`NCT01044966` - A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma	Phase 1/Phase 2
Terminated	`NCT00990496` - A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)	Phase 1
Completed	`NCT00402116` - Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients	Phase 1/Phase 2
Completed	`NCT00112502` - Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme	Phase 2
Completed	`NCT00504660` - 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients	Phase 2
Recruiting	`NCT05366179` - Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc	Phase 1